GSK (GSK) Bank of America Global Healthcare Conference summary

Strategic priorities and financial targets

• Accelerating growth and asset development is a key focus, with a GBP 1.9 billion self-funded savings program to support pipeline investments and margin stability through 2028-2030.

• Seven major assets across 18 indications are prioritized, with oncology highlighted as a significant growth area.

• Sales growth above 7% and profit growth above 11% are expected for 2021-2026, alongside a margin improvement of over 500 basis points and increased R&D investment.

• Specialty business is projected to exceed 50% of the portfolio by 2031, supporting margin accretion.

• Margin improvements are driven by productivity initiatives, SG&A reductions, and a shift toward specialty products.

Product launches and pipeline updates

• Excentia, a six-month biologic for severe asthma, is expected to see an inflection in uptake in Q4 as administrative and payer barriers are removed.

• BLENREP, for multiple myeloma, is positioned for gradual growth due to its unique administration and side effect profile, with stronger uptake expected over time.

• Bepirovirsen for hepatitis B offers a functional cure for 19% of patients and is seen as transformational, with launches in Japan and anticipated approval in China by mid-2027.

• Nuvalent assets, including zidesamtinib and neladalkib, are progressing well, with strong U.S. launch preparation and promising data, especially for neladalkib in ALK-positive cancer.

• Nucala's broad label and comorbidity coverage support its strong performance in COPD and severe asthma.

Market dynamics, headwinds, and competitive landscape

• Oncology is the main area of forecast divergence with consensus, particularly in the ADC portfolio and BLENREP.

• TRELEGY faces a major headwind in 2027 due to IRA-related pricing impacts, though the effect is mitigated by high rebates.

• SHINGRIX growth continues globally, but higher base effects make further acceleration challenging.

• HIV portfolio faces gradual erosion in smaller markets, but long-acting injectables are favored by patients and physicians, supporting resilience.

• AstraZeneca's COPD data is acknowledged, but Nucala's comprehensive label and comorbidity coverage are seen as competitive advantages.